Near-Infrared Optical Imaging of Integrin αvβ3 in Human Tumor Xenografts
暂无分享,去创建一个
Eva M. Sevick-Muraca | Shi Ke | Juri G. Gelovani | Qingping Wu | Wei Wang | James L. Abbruzzese | C. Charnsangavej | E. Sevick-Muraca | J. Abbruzzese | J. Gelovani | S. Ke | Chun Li | Mikhail Gurfinkel | Chun Li | Wei Wang | Chusilp Charnsangavej | M. Gurfinkel | Qingping Wu
[1] E Ruoslahti,et al. New perspectives in cell adhesion: RGD and integrins. , 1987, Science.
[2] D. Cheresh. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Ruiter,et al. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice , 2007, International journal of cancer.
[4] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[5] D. Cheresh,et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.
[6] H. Bergh,et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. , 1994, Cancer research.
[7] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[8] D. Cheresh,et al. Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.
[9] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[10] J. Brugge,et al. Integrins and signal transduction pathways: the road taken. , 1995, Science.
[11] A. Halpern,et al. A Prognostic Model for Predicting 10-Year Survival in Patients with Primary Melanoma , 1996, Annals of Internal Medicine.
[12] A. Shilkaitis,et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. , 1996, The Journal of surgical research.
[13] M. Bednarski,et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.
[14] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[15] M. Schwaiger,et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] R. Weissleder,et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.
[17] J. Schneider-Mergener,et al. Cyanine Dye Labeled Vasoactive Intestinal Peptide and Somatostatin Analog for Optical Detection of Gastroenteropancreatic Tumors , 2000, Annals of the New York Academy of Sciences.
[18] S. Achilefu,et al. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. , 2000, Investigative radiology.
[19] M. Schwaiger,et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. , 2001, Cancer research.
[20] Robert E. Lenkinski,et al. In vivo near-infrared fluorescence imaging of osteoblastic activity , 2001, Nature Biotechnology.
[21] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] Christoph Ballestrem,et al. Marching at the front and dragging behind , 2001, The Journal of cell biology.
[23] Milind Rajopadhye,et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.
[24] R. Weissleder,et al. Charge-coupled-device based scanner for tomography of fluorescent near-infrared probes in turbid media. , 2002, Medical physics.
[25] Chun Li,et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.
[26] R. Taillefer,et al. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients With acute deep vein thrombosis or a history of deep vein thrombosis. , 2003, Archives of internal medicine.
[27] E. Sevick-Muraca,et al. Near-Infrared Fluorescence Optical Imaging and Tomography , 2004, Disease markers.
[28] Shelton D Caruthers,et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. , 2003, Cancer research.
[29] Ryan Park,et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.
[30] J. Bading,et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.
[31] A B Thompson,et al. Diagnostic imaging of breast cancer using fluorescence-enhanced optical tomography: phantom studies. , 2004, Journal of biomedical optics.
[32] M. Schwaiger,et al. Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. , 2004, Nuklearmedizin. Nuclear medicine.
[33] M. Schwaiger,et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.
[34] Daniel L. Farkas,et al. Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies , 1995, Cancer Immunology, Immunotherapy.